PharOS Overview

  • Founded

  • 2002

Founded
  • Status

  • Private

  • Employees

  • 187

Employees
  • Latest Deal Type

  • PE Growth

  • Financing Rounds

  • 1

PharOS General Information

Description

Manufacturer of generic pharmaceutical and value-added products intended to extend the lifecycle of the product. The company offers various products including antivirals, antidiabetics, antipsychotics, antidepressants and oncology medicines that are sold throughout the world to meet the pharma industry's demanding requirements, ensuring its clients with the success in completing challenging projects through intellectual property rights and developments.

Contact Information

Website
www.pharosgr.gr
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
  • Lesvou Street, Thesi Loggos
  • Industrial Zone
  • Metamorfossi Attikis, 144 52
  • Greece
+30 21 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PharOS Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PharOS‘s full profile, request access.

Request a free trial

PharOS Patents

  • 5

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

PharOS Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3793530-A1 Solid dispersion containing ritonavir Pending 18-May-2018 0000000000
EP-3569225-A1 Solid dispersion containing ritonavir Withdrawn 18-May-2018 0000000000
EP-3419605-A1 Dasatinib formulation Pending 25-Feb-2016 0000000000
GB-201304699-D0 Pharmaceutical compositions Ceased 15-Mar-2013 0000000000
EP-2968175-A1 Pharmaceutical compositions comprising imatinib Withdrawn 15-Mar-2013 A61K31/506
To view PharOS’s complete patent history, request access »

PharOS Executive Team (5)

Name Title Board Seat Contact Info
Alexis Rizos Chief Financial Officer
Stella Koukaki Co-Founder, Co-Owner, Managing Partner, Managing Director & Scientific Affairs Director
Panagiotis Panagopoulos Ph.D Co-Owner, Managing Partner & Director, Research & Development
Theodore Panagopoulos Co-Owner, Partner & Director, Commercial
You’re viewing 4 of 5 executive team members. Get the full list »

PharOS Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PharOS Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore PharOS‘s full profile, request access.

Request a free trial